United States, Nov. 6 -- The U.S. Food and Drug Administration announced six additional awardees under the Commissioner's National Priority Voucher (CNPV) pilot program. This second cohort brings the total number of voucher recipients to 15, underscoring the agency's commitment to accelerating the review of products with the potential to address key national priorities. Upon submission of a complete application, national priority voucher holders will receive a decision within months, a drastic reduction of the typical review timeline. The faster timeframe is contingent upon additional requirements from the company, and FDA staff reserve the right to extend the review as needed.The cornerstone of the accelerated timeline is a one-day "tumor ...